Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

SAB World of Learning Brewery bid awarded to Kovsie Brewing
2017-11-28

Description: Kovsie Brewing 2 2017 Tags: Kovsie Brewing 2 2017 

Visitors from SA Breweries (AB InBev), Khosi Mogotsi,
Patience Selesho and Zinhle Ngcobo with
Dr Jan-G Vermeulen and Dr Errol Cason from
Kovsie Brewery.
Photos: Moeketsi Mogotsi

With the recent procurement of SAB by Anheuser-Busch InBev SA/NV (AB InBev), a Belgian transnational beverage and brewing company, the 500L educational brewery located at the SAB Cyril Ramaphosa World of Learning, became available for donation. After an initial shortlisting of three universities, the SAB World of Learning Brewery was awarded to the University of the Free State (UFS) to be managed by Kovsie Brewing.

Prof Corli Witthuhn, Vice-Rector: Research at the UFS, approved the application for a micro-manufacturing liquor licence right in the middle of campus, which effectively put the UFS bid in a class of its own. It is part of her vision that entrepreneurial activities must be visible on campus”

Sixteen universities were approached to obtain the brewery for their respective campuses.

Kovsie Brewing is an initiative started by postgraduate students at the UFS Department of Microbial, Biochemical and Food Biotechnology in 2012. The main objective of this initiative was to expose BSc students to brewing as a practical application of the scientific fields presented at the department.
 

Description: Kovsie Brewing 1 2017 Tags: Kovsie Brewing 1 2017 

Label mock-ups made by
Dr Jan-G Vermeulen from
Kovsie Brewery entered into
the yearly  SAB Intervarsity
Brewing Competition. Kovsie
Brewing has won the best label
competition in 2013, 2014 and 2015
and was placed in the top three in
2016 and 2017.


First brewing and fermentation school
Dr Errol Cason, project leader at Kovsie Brewery, said: “Over the past five years the small-scale experimental brewery has steadily grown to the point where we obtained institutional support to establish the first Brewing and Fermentation School at the university.

Dr Cason explains that the primary role of Kovsie Brewing is to establish an accredited fermentation-based curriculum at the UFS to educate undergraduate and postgraduate students in the scientific process involved in the production of beer. “In addition, the donation enables Kovsie Brewing to provide practical job-related training and skills development on industrial grade equipment,” he said.

Emphasis on entrepreneurship
The secondary role is for Kovsie Brewing to function as a multi-disciplinary platform to stimulate the interaction between students from various fields of study. Currently Kovsie Brewing has well-established cooperative projects with both Marketing and Entrepreneurship programmes.

“In the future, Kovsie Brewing will expand on these multi-disciplinary interactions by incorporating other departments of the UFS with the focus on product development, logistics, as well as the legal aspects concerned with brewing,” Dr Jan-G Vermeulen from the Kovsie Brewery team said.

Corporate social investment representatives from AB InBev recently visited the university. Among others they met Drs Vermeulen and Cason. During their visit they also looked at other university projects, including the Department of Paediatric and Child Health and the Universitas Hospital, the Engineering Sciences Department and the Naval Hill Planetarium.

Khosi Mogotsi from AB InBev said: “It was wonderful to experience the passion with which UFS staff do their work.”

 

 

 

 

 

 

 

 

 

 

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept